排名前五的靶点	数量

COX-1 x COX-2	1
水解酶 x SARS-CoV-2 antigen x norovirus 3CL protease	1
FLT3(酪氨酸蛋白激酶受体FLT3)	1
GnRHR(促性腺激素释放激素受体)	1
CLDN18.2(Claudin 18.2蛋白)	1

关联

项与石家庄以岭药业股份有限公司相关的药物

Qifangbitong Tablets

芪防鼻通片

靶点-

作用机制-

在研机构

北京以岭药业有限公司 [+1]

原研机构

石家庄以岭药业股份有限公司 [+1]

在研适应症

常年性变应性鼻炎

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2025-01-14

Tongluo Mingmu Capsules

通络明目胶囊

靶点-

作用机制-

在研机构

石家庄以岭药业股份有限公司

原研机构

石家庄以岭药业股份有限公司

在研适应症

非增殖性糖尿病视网膜病变

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2023-10-19

ShenSongYangXin

参松养心

靶点-

作用机制-

在研机构

石家庄以岭药业股份有限公司

原研机构

石家庄以岭药业股份有限公司

在研适应症

心律失常 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

肯尼亚

首次获批日期2023-06-27

项与石家庄以岭药业股份有限公司相关的临床试验

CTR20252103

/ Completed临床1期

评价食物对G201-Na胶囊在中国健康研究参与者中药代动力学影响的随机、开放、两周期、交叉设计I期临床研究

主要目的：评价食物对中国健康研究参与者单次口服G201-Na胶囊药代动力学的影响。次要目的：评价健康研究参与者单次口服G201-Na胶囊的安全性。

开始日期2025-06-03

申办/合作机构

石家庄以岭药业股份有限公司

CTR20243918

/ Recruiting临床2期

连花清咳颗粒治疗儿童急性支气管炎（痰热壅肺证）有效性和安全性的随机、双盲、低剂量对照、多中心Ⅱ期临床研究

（1）评价连花清咳颗粒在儿童急性支气管炎（痰热壅肺证）缩短病程、缓解支气管炎病情/症状体征和改善中医证候的作用。（2）观察连花清咳颗粒临床应用的安全性。

开始日期2024-12-16

申办/合作机构

石家庄以岭药业股份有限公司

CTR20244086

/ Recruiting临床2期

评价XY03-EA片治疗急性缺血性卒中有效性及安全性的多中心、随机、双盲、安慰剂平行对照Ⅱb/Ⅲ期临床研究

Ⅱb期研究阶段：主要目的：探索XY03-EA片不同剂量治疗急性缺血性卒中的有效性及安全性，为Ⅲ期临床研究提供数据支持。次要目的： 1）探索XY03-EA片治疗急性缺血性卒中的给药疗程； 2）基于群体PK分析方法，探索XY03-EA及其代谢产物在急性缺血性卒中患者中的PK特性。 Ⅲ期研究阶段：主要目的：确证XY03-EA片治疗急性缺血性卒中的有效性。次要目的： 1）进一步评价XY03-EA片治疗急性缺血性卒中的安全性。 2）基于群体PK分析方法，探索XY03-EA及其代谢产物在急性缺血性卒中患者中的PK特性。

开始日期2024-12-15

申办/合作机构

石家庄以岭药业股份有限公司

100 项与石家庄以岭药业股份有限公司相关的临床结果

登录后查看更多信息

0 项与石家庄以岭药业股份有限公司相关的专利（医药）

登录后查看更多信息

155

项与石家庄以岭药业股份有限公司相关的文献（医药）

2025-12-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Molecular insights into the anti-asthma potential of Zhimu-Chuanbeimu drug pair based on serum pharmacochemistry, network pharmacology and immune infiltration analysis

Article

作者: Xing, Yiqi ; Zhang, Huiyi ; Cui, Qingfei ; Tian, Xi ; Jin, Yiran ; Wei, Jinhuan ; Wang, Jiayi ; Zhang, Chunli ; Du, Yingfeng ; Yang, Mengxin ; Chen, Xueyi ; Li, Wenyu

In traditional Chinese Medicine, Zhimu-Chuanbeimu (ZC) is one of the most classical herb pairs used in the treatment of lung diseases such as asthma. This study aimed to elucidate its specific components and potential mechanisms involved in treating asthma by altering the immune microenvironment. A systematic analysis of the chemical substance and absorbent components were conducted using UHPLC-Q-TOF-MS. Subsequently, a targeted network pharmacology based on serum pharmacochemistry was employed to predict core targets and key active ingredients. By combining microarray data analysis and gene set enrichment analysis, key targets and immune environment changes were further clarified. Ultimately, the prediction mechanism was validated through molecular docking, molecular dynamic simulations, and in vivo experiment validation. Consequently, sixty-seven prototype substances were identified in the blood samples of normal rats. Through network pharmacology and microarray data analysis, CCND1 and ESR1 were selected as key targets. Gene set enrichment analysis indicated that the expression of CCND1 was correlated with T helper cells, while the expression of ESR1 was positively correlated with mast cells. Additionally, the molecular docking and molecular dynamic simulations effectively supported the binding affinity between puqienine C and markogenin with the binding pockets of CCND1 and ESR1. Finally, in vivo experiments revealed that ZC extract could improve airway hyperresponsiveness, pulmonary inflammatory infiltration, the expression of CCND1/ESR1 and Th1/Th2/Th17/Treg imbalance in OVA-induced asthma rats. In conclusion, this research uncovered the pharmacodynamic foundation of ZC and its potential multifaceted pharmacological impacts, indicating that its potential anti-asthma mechanism might involve the modulation of immune cells and associated inflammatory pathways. Moreover, it provided a benchmark for enhancing asthma treatment protocols.

2025-07-01·JOURNAL OF ETHNOPHARMACOLOGY

A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of Yuping Tongqiao tablets in the treatment of persistent allergic rhinitis

Article

作者: Jiang, Qingshan ; Yang, Xiangli ; Tang, Jinyong ; Jiang, Luyun ; Wang, Renzhong ; Cheng, Jinlian ; Huang, Chunjiang ; Wang, Man ; He, Jianqiao ; Liu, Zhaohui ; Cheng, Xiangrong ; Li, Xuezhong ; Yang, Yi ; Liu, Weiwei ; Han, Jianke ; Chen, Xiaoning ; Sun, Li ; Wang, Ningbo ; Yan, Zhanfeng ; Liang, Gengtian ; Dong, Yaowu ; Zhu, Zhenhua ; Wang, Guangke ; Chen, Jianjun ; Li, Guang ; Song, Xicheng ; Wang, Junge ; Yu, Bin ; Lu, Biaoqing ; Li, Xiangsheng ; Deng, Chengcheng ; Peng, Lifen ; Dong, Hongjun ; Liu, Wen ; Ye, Jing

ETHNOPHARMACOLOGICAL RELEVANCE:

Yuping Tongqiao Tablets is a classic traditional Chinese medicine (TCM) formula commonly employed in China for managing various ailments, especially allergic conditions. Clinical reports indicate its potential as an effective treatment for persistent allergic rhinitis. Nevertheless, there remains a dearth of placebo-controlled studies to definitively establish its safety and efficacy.

AIMS OF THE STUDY:

Allergic rhinitis (AR) is a global health problem with an annually increasing prevalence and no radical cure to date. This study aimed to evaluate the efficacy and safety of Yuping Tongqiao tablets for the treatment of persistent allergic rhinitis and to provide a basis for using Chinese herbal medicine to treat AR.

MATERIALS AND METHODS:

This was a multicenter, randomized, double-blind, placebo-controlled study of patients with PAR. A total of 540 patients with PAR were randomly assigned to the test group (n = 360) or the placebo group (n = 180) at a 2:1 ratio. The clinical trial lasted for 4 weeks, evaluating various outcomes including total nasal symptom scores, rhinoconjunctivitis quality of life questionnaire (RQLQ) scores, traditional Chinese medicine (TCM) symptom scores and The incidence of adverse events.

RESULTS:

A total of 768 participants were enrolled, with 540 randomized and 516 successfully completed the research. The experimental group using Yuping Tongqiao tablets showed a significant reduction in TNSS, with the least squares mean of the average decrease being -2.56 points, compared to -1.74 points in the placebo group (p < 0.01). The experimental group exhibited a higher nasal symptom response rate at 4 weeks, substantial clinical improvements, and notable enhancements in TCM symptoms and RQLQ scores. Treatment efficacy increased with duration, and adverse events were mild-to-moderate and occurred at similar rates in both groups.

CONCLUSION:

Yuping Tongqiao tablets have been proven to be an effective and safe medication for the treatment of PAR.

TRIAL REGISTRATION:

ChiCTR, ChiCTR2200061367. Registered June 22, 2022.

2025-07-01·PHYTOMEDICINE

Deciphering the molecular mechanisms of QLQX capsules in heart failure: A multi-omics perspective

Article

作者: Hao, Jiameng ; Song, Tao ; Hao, Yuanyuan ; Wang, Mingye ; Hou, Yunlong ; Chang, Liping ; Jia, Zhenhua ; Wu, Qiulan

PURPOSE:

This study investigates the therapeutic mechanisms of Qiliqiangxin (QLQX) capsules in treating Heart Failure with Preserved Ejection Fraction (HFpEF). The study aims to understand how QLQX impacts cardiac function and underlying molecular pathways.

METHODS:

HFpEF was induced in a rat model through unilateral nephrectomy, DOCA pellet implantation, and a high-salt diet. Cardiac function was assessed via M-mode imaging and Doppler flow measurements, focusing on key parameters like ejection fraction and diastolic function. A network pharmacology approach identified active QLQX components and potential targets, followed by comprehensive multi-omics analyses-including transcriptomics, proteomics, and metabolomics-to uncover the molecular mechanisms modulated by QLQX. Quantitative RT-PCR was employed to measure mRNA levels of key cardiac markers, providing further insights into QLQX's impact on cardiac remodeling.

RESULTS:

QLQX treatment significantly improved cardiac function, with notable enhancements in ejection fraction and left ventricular diastolic function. Network pharmacology revealed 530 potential targets of QLQX, with 38 overlapping HFpEF targets. Key pathways identified include cGMP-PKG, adrenergic signaling, and calcium signaling. Transcriptomic analysis showed significant gene expression changes related to inflammation, energy metabolism, and myocardial remodeling, which were reversed by QLQX. Proteomic analysis identified 401 differentially expressed proteins, enriched in pathways such as cGMP-PKG and NF-κB signaling. Metabolomic profiling highlighted the role of lipid metabolism and adrenergic signaling in HFpEF, which were normalized by QLQX. In vivo validation confirmed the involvement of the cGMP-PKG pathway, with increased serum NO and cGMP levels, improved endothelial function, and reduced pro-fibrotic markers following QLQX treatment.

CONCLUSION:

QLQX exerts multifaceted therapeutic effects on HFpEF by modulating gene expression, protein function, and metabolic pathways, particularly through the cGMP-PKG signaling pathway. These findings support QLQX as a promising therapeutic intervention for HFpEF, offering improvements in cardiac function and reversing pathological changes at multiple molecular levels.

1,552

项与石家庄以岭药业股份有限公司相关的新闻（医药）

2025-08-14

·同写意

易慕峰实体瘤CAR-T发表最新研究成果 | 会员动态

免疫疗法细胞疗法临床1期

2025-08-14

·同写意

瀚枢生物：提供一站式神经系统药物研发解决方案 | 写意会员

临床申请

2025-08-13

·同写意

国产首款，如何成就？

上市批准

100 项与石家庄以岭药业股份有限公司相关的药物交易

登录后查看更多信息

100 项与石家庄以岭药业股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床申请

临床1期

临床2期

临床3期

申请上市

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

通心络	心律失常更多	批准上市
芪苈强心	心律失常更多	批准上市
连花清瘟胶囊	流感病毒感染更多	批准上市
参松养心	心律失常更多	批准上市
芪防鼻通片	常年性变应性鼻炎更多	批准上市